CA Patent

CA2648604A1 — Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor

Assigned to Opko Health Inc · Expires 2007-10-18 · 19y expired

What this patent protects

Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8- [{(1R)-1 -(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7- diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.

USPTO Abstract

Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8- [{(1R)-1 -(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7- diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.

Drugs covered by this patent

Patent Metadata

Patent number
CA2648604A1
Jurisdiction
CA
Classification
Expires
2007-10-18
Drug substance claim
No
Drug product claim
No
Assignee
Opko Health Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.